Halozyme(HALO) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Royalty Revenue Increased 21% YOY to $121 million Reiterating 2024 Financial Guidance: Total Revenue of$ 915 - $985 million, Representing YOY Growth of 10% - 19%, Adjusted EBITDA of$ 535 - $585 million, Representing YOY Growth of 26% - 37% and Non-GAAP Diluted EPS of$ 3.55 - $3.90, Representing YOY Growth of 28% - 41% Announced New$ 750 million Share Repurchase Program SAN DIEGO, May 7, 2024 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial ...